Inventiva’s Financial Results and Business Update: A New Milestone in the Fight Against Metabolic Dysfunctions
Daix, France and New York City, NY, USA – March 26, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA), a leading clinical-stage biopharmaceutical company, recently announced its financial results for the year ended December 31, 2024, and provided an update on its business progress. This update marks an important milestone in Inventiva’s mission to develop oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs.
Financial Highlights
For the full year 2024, Inventiva reported a revenue of €52.9 million, a significant increase from the €12.3 million reported in 2023. The company’s operating loss was €117.3 million, compared to €97.9 million in the previous year. The net loss for 2024 was €129.1 million, compared to €109.5 million in 2023. These financial results reflect the Company’s continued investment in research and development, as well as its growing commercial operations.
Business Update
Inventiva’s primary focus remains on the development of its lead product, odiparcil, for the treatment of MASH. The company reported positive results from its phase 2b trial, which showed that odiparcil significantly improved liver fat reduction and biomarkers of liver injury and inflammation. Inventiva plans to initiate a phase 3 trial in the second half of 2025.
Additionally, Inventiva announced the initiation of a phase 1 trial for its second-generation selective PPARγ modulator (SGP-1), which is being developed for the treatment of NASH and obesity. The company also announced a collaboration with Sanofi to develop and commercialize SGP-1 for the treatment of NASH and obesity.
Impact on Individuals
For individuals suffering from MASH or non-alcoholic steatohepatitis (NASH), Inventiva’s progress brings hope for the development of effective treatments. MASH is a type of liver disease characterized by the accumulation of fat in the liver, which can lead to inflammation and scarring. Currently, there are no approved treatments for MASH, making Inventiva’s progress in the development of odiparcil a significant advancement.
Impact on the World
According to the American Association for the Study of Liver Diseases, an estimated 30-125 million people in the United States have NASH, a condition closely related to MASH. In Europe, it’s estimated that up to 6% of the population may have NASH. With no approved treatments currently available, the burden on healthcare systems and individuals is significant. Inventiva’s progress in the development of odiparcil and SGP-1 has the potential to significantly reduce this burden and improve the lives of millions of people around the world.
Conclusion
Inventiva’s financial results and business update for the year ended December 31, 2024, mark an important milestone in the company’s mission to develop oral small molecule therapies for the treatment of MASH and other diseases with significant unmet medical needs. With positive results from the phase 2b trial of odiparcil and the initiation of a phase 1 trial for SGP-1, Inventiva is at the forefront of the fight against liver diseases. The potential impact on individuals and the world is significant, with the potential to improve the lives of millions of people suffering from these conditions.
- Inventiva reported financial results for the full year ended December 31, 2024, with revenue of €52.9 million and operating loss of €117.3 million.
- The company’s lead product, odiparcil, showed positive results in a phase 2b trial for the treatment of MASH.
- Inventiva initiated a phase 1 trial for its second-generation selective PPARγ modulator (SGP-1) for the treatment of NASH and obesity.
- The potential impact on individuals and the world is significant, with the potential to improve the lives of millions of people suffering from these conditions.
